Merck's Anacetrapib Survives Futility Exam, But Will It Pass Final Test?

Merck & Co. Inc. has been fairly tight-lipped about its cholesteryl ester transfer protein (CETP) inhibitor anacetrapib for hypercholesterolemia while the 30,000-patient Phase III REVEAL clinical trial is ongoing, but the company said on Nov. 13 that the drug passed a recent futility test.